Get the Stockscreener App
2.96
7.21%
-0.23
Voyager Therapeutics Inc stock is traded at $2.96, with a volume of 872.93K.
It is down -7.21% in the last 24 hours and down -5.13% over the past month.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$3.19
Open:
$3.15
24h Volume:
872.93K
Relative Volume:
1.36
Market Cap:
$163.80M
Revenue:
$163.78M
Net Income/Loss:
$25.88M
P/E Ratio:
4.5538
EPS:
0.65
Net Cash Flow:
$-28.66M
1W Performance:
-8.64%
1M Performance:
-5.13%
6M Performance:
-45.69%
1Y Performance:
-65.90%
1-Day Range:
$2.95
$3.17
1-Week Range:
$2.95
$3.79
52-Week Range:
$2.645
$8.53
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
2.96 | 176.52M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
How many analysts rate Voyager Therapeutics Inc. as a “Buy”Wealth Building Data Feed For Every Investor - jammulinksnews.com
What are the latest earnings results for Voyager Therapeutics Inc.Chart Pattern Report Backed By Experts - jammulinksnews.com
How does Voyager Therapeutics Inc. generate profit in a changing economyBeginner Investor Alerts For Fast Growth - jammulinksnews.com
How does Voyager Therapeutics Inc. compare to its industry peersExpert Picks Tracker From AI Tools - jammulinksnews.com
Voyager Therapeutics Inc. Added to High Probability Setup ListBuy Signal Based on Chart Analysis Confirmed - metal.it
Voyager Therapeutics Inc. Tests 50 Day MA After Sharp DeclineQuick Gain Stock Watch With Indicators Reviewed - metal.it
Published on: 2025-07-29 08:53:38 - metal.it
Is Voyager Therapeutics Inc. a growth stock or a value stockAI Powered Target Finder For Consistent Profits - jammulinksnews.com
Top Risks to Consider Before Buying Voyager Therapeutics Inc. StockPortfolio Diversification Stock Ideas From Experts - metal.it
Pattern Scan Adds Voyager Therapeutics Inc. to WatchlistMarket Entry and Exit Point Tips From Traders - metal.it
What institutional investors are buying Voyager Therapeutics Inc. stockPost Market Review For 2025 - jammulinksnews.com
What are Voyager Therapeutics Inc. company’s key revenue driversEntry Signal Report For Beginners - jammulinksnews.com
What is the risk reward ratio of investing in Voyager Therapeutics Inc. stockBuild a winning investment strategy - jammulinksnews.com
Why Voyager Therapeutics Inc. stock attracts strong analyst attentionWatchlist for Smart Swing Trading Updated - metal.it
What catalysts could drive Voyager Therapeutics Inc. stock higher in 2025Massive stock growth - jammulinksnews.com
What are analysts’ price targets for Voyager Therapeutics Inc. in the next 12 monthsUnlock exclusive stock analysis for investors - jammulinksnews.com
What is the dividend policy of Voyager Therapeutics Inc. stockFree Investment Community - jammulinksnews.com
Is Voyager Therapeutics Inc. a good long term investmentTremendous wealth creation - PrintWeekIndia
What analysts say about Voyager Therapeutics Inc. stockFree Stock Market Knowledge Sharing - PrintWeekIndia
How high can Voyager Therapeutics Inc. stock price go in 2025Rapid return acceleration - jammulinksnews.com
What drives Voyager Therapeutics Inc. stock priceFree Capital Efficiency Planning - Autocar Professional
Voyager Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com
Voyager Therapeutics’ Promising Alzheimer’s Study: A Potential Game-Changer? - MSN
Voyager Therapeutics: A High-Conviction Biotech Play in the Tau-Targeting Alzheimer's Revolution - AInvest
Why did Voyager's net profit surge in Q4 2024 despite high operating expenses? - AInvest
Does Voyager Therapeutics Inc. stock pay reliable dividendsTrend Based Entry Alerts - beatles.ru
Baird Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
Voyager Therapeutics (VYGR) Gets a Buy from Robert W. Baird - The Globe and Mail
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Voyager Therapeutics Inc Stock (VYGR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO |
Apr 02 '25 |
Sale |
3.43 |
10,885 |
37,336 |
430,931 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):